Barinthus Bio shares surge 12.11% premarket on positive Phase 1 AVALON trial update for VTP-1000 celiac treatment.

Barinthus Bio (NASDAQ: BRNS) surged 12.11% in premarket trading following the announcement of positive Phase 1 AVALON trial results for its experimental celiac disease treatment VTP-1000. The single ascending dose (SAD) portion of the trial demonstrated a dose-dependent pharmacological effect, with no treatment-related serious adverse events reported. The therapy, which uses Barinthus’s SNAP-TI platform to deliver gluten-derived peptides and rapamycin in nanoparticles, showed immune recognition without significant inflammation, as highlighted by a robust IL-2 response across all dose levels. The multiple ascending dose (MAD) phase, including a gluten challenge, remains ongoing, with data expected in late 2026. The company emphasized the potential of VTP-1000 to address a high-unmet-need condition, as celiac disease currently has no approved treatments. The results position Barinthus as a leader in antigen-specific immune tolerance therapies, fueling optimism about the candidate’s disease-modifying potential.